STOCK TITAN

Biocryst Pharmaceuticals Inc. - BCRX STOCK NEWS

Welcome to our dedicated news page for Biocryst Pharmaceuticals (Ticker: BCRX), a resource for investors and traders seeking the latest updates and insights on Biocryst Pharmaceuticals.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Biocryst Pharmaceuticals's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Biocryst Pharmaceuticals's position in the market.

Rhea-AI Summary
BioCryst Pharmaceuticals grants stock options and RSUs to newly-hired employees
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.16%
Tags
none
-
Rhea-AI Summary
BioCryst Pharmaceuticals to present at Wells Fargo Healthcare Conference and H.C. Wainwright Global Investment Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.69%
Tags
conferences
-
Rhea-AI Summary
BioCryst Pharmaceuticals, Inc. has granted seven newly-hired employees stock options to purchase 38,600 shares and restricted stock units (RSUs) covering 26,450 shares of BioCryst common stock. The options and RSUs were granted as inducements for the employees to join the company. The options have an exercise price of $7.39 per share, and both options and RSUs vest in four equal annual installments starting from the one-year anniversary of the grant date.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
BioCryst Pharmaceuticals reported Q2 2023 net revenue of $81.0 million, a 24% increase YoY. They are on track to achieve ≥ $320 million in full year 2023 ORLADEYO revenue and $1 billion in peak ORLADEYO revenue. The company plans to introduce additional pipeline assets and programs at their R&D day in November.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.87%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.58%
Tags
conferences earnings
-
Rhea-AI Summary
BioCryst Pharmaceuticals has partnered with Er-Kim Pharmaceuticals to commercialize ORLADEYO in Turkey. This collaboration will help make the oral, once-daily prophylactic treatment available to patients with hereditary angioedema (HAE) in the Turkish market.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.65%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.84%
Tags
conferences
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.14%
Tags
none
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.03%
Tags
none
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.45%
Tags
conferences
Biocryst Pharmaceuticals Inc.

Nasdaq:BCRX

BCRX Rankings

BCRX Stock Data

950.35M
190.88M
1.21%
88.11%
15.65%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Durham

About BCRX

biocryst pharmaceuticals, a biotechnology company, designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. founded in 1986, biocryst has more than 50 employees and is experiencing continued growth. the company’s headquarters are located in research triangle park, north carolina and its discovery center of excellence is in birmingham, alabama. with expertise in drug discovery, clinical development, regulatory affairs and product commercialization, we continue to advance our clinical programs and to generate new compounds from our own discovery engine. we are proud of our culture of engagement and accountability that rewards people for innovative thinking and achievement of key objectives. the commitment of biocryst remains unchanged. we continue to be passionate about developing and marketing novel therapeutics for patients with rare and serious diseases.